Published in Cancer Res on April 01, 1975
Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. Br J Cancer (1982) 0.75
Plaque forming cells: methodology and theory. Transplant Rev (1974) 3.92
Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res (1993) 2.20
Sublethal ischemia alters myocardial antioxidant activity in canine heart. Am J Physiol (1993) 1.30
Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res (1969) 1.26
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J (1974) 1.15
Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas. Cancer Res (1982) 1.12
Evidence for multigenic control of immune response to theta-AKR antigen in mice. Transplant Proc (1973) 1.09
Immune response to alloantigens of thymus studied in mice with plaque assay. J Immunol (1971) 1.02
Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (1980) 1.00
Daily oral care and risk factors for pneumonia among elderly nursing home patients. JAMA (2001) 1.00
Modification of tumor regression by immunologic means. Cancer Res (1969) 0.99
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res (1988) 0.97
Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon. Cancer Res (1987) 0.93
Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen. J Immunol (1986) 0.92
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res (1992) 0.91
Genetic control of immune response to theta-AKR alloantigen. J Immunol (1972) 0.90
Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1978) 0.89
Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res (1989) 0.89
Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res (1992) 0.88
Effects of anticancer drugs on the immune system in humans. Semin Oncol (1989) 0.88
Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer (1994) 0.88
Detection of oxygen-derived free radical generation in the canine postischemic heart during late phase of reperfusion. Circ Res (1990) 0.88
Role of free radicals and neutrophils in canine myocardial reperfusion injury: myocardial salvage by a novel free radical scavenger, 2-octadecylascorbic acid. Cardiovasc Res (1989) 0.88
Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res (1977) 0.88
Toxicological and antiproliferative effects of N6-(delta2-isopentenyl) adenosine, a natural component of mammalian transfer RNA. Cancer Res (1970) 0.87
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine. Biochem Pharmacol (1978) 0.87
Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer (2000) 0.87
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res (1986) 0.86
Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens. Cancer Res (1986) 0.86
A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. Int J Immunopharmacol (2000) 0.85
Neutrophil-induced myocardial cell damage and active oxygen metabolites. Jpn Circ J (1991) 0.85
Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol (1994) 0.85
Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res (1989) 0.85
Influence of inoculation site on development of the Lewis lung carcinoma and suppressor cell activity in syngeneic mice. J Natl Cancer Inst (1979) 0.85
Plaque assay with spleen cells forming alloantibodies to H-2 a and H-2 d specificities. Transplantation (1973) 0.84
Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts. Cancer Res (1986) 0.84
Apoptosis induced by DNA uptake limits transfection efficiency. Exp Cell Res (1999) 0.83
Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer (2000) 0.83
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1998) 0.83
Primary immune response in vitro: reversible suppression by anti-globulin antibodies. Ann Inst Pasteur (Paris) (1969) 0.83
Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. J Leukoc Biol (2001) 0.83
Cytolysis in agar of thymus cells by antibody-forming cells. Proc Soc Exp Biol Med (1970) 0.82
Fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1975) 0.82
Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. Int J Immunopharmacol (1982) 0.81
Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. Int J Immunopharmacol (1982) 0.81
The clinical toxicity of anticancer drugs and its prediction. Semin Oncol (1977) 0.81
Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol (1983) 0.81
Effect of splenectomy on the regression of transplantable tumors. Cancer Res (1968) 0.81
Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res (1988) 0.81
Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta). J Immunol (1987) 0.81
Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity. Cancer Immunol Immunother (1983) 0.80
Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res (1972) 0.80
Usefulness of plasma brain natriuretic peptide after acute myocardial infarction in predicting left ventricular dilatation six months later. Am J Cardiol (2001) 0.80
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother (1996) 0.80
Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer (1995) 0.80
Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Regul (1978) 0.80
Radioresponse of thymomas verified with histologic response. Acta Oncol (1998) 0.80
Brief myocardial ischemia affects free radical generating and scavenging systems in dogs. Heart Vessels (1993) 0.80
Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer (1998) 0.79
Toxic and patologic effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone), a new antileukemic agent. Cancer Res (1969) 0.79
Lipopolysaccharide and splenic tumoricidal macrophage activation. J Leukoc Biol (1994) 0.79
Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. Int J Immunopharmacol (1988) 0.79
Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine. Cancer Res (1969) 0.79
Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. FASEB J (2001) 0.79
[Cephalometric changes in treatment of anterior crossbite cases with the chin cap]. Nihon Kyosei Shika Gakkai Zasshi (1972) 0.78
Induction of suppressor T cells in culture--I. Cell-cell interactions. Int J Immunopharmacol (1984) 0.78
The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol (1983) 0.78
Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. Cancer Res (1972) 0.78
Selective effects of Adriamycin on murine host defense systems. Immunol Rev (1982) 0.78
Polymyxin B-mediated lysis of tumor cells. Int Arch Allergy Immunol (1993) 0.78
Plaque-forming-cell response to H-2 antigens of mice. Proc Soc Exp Biol Med (1971) 0.78
Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res (1999) 0.78
Immunologic injury of renal homografts. J Exp Med (1971) 0.78
Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol (1995) 0.78
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas. Oncol Res (1993) 0.78
Differences in the immunogenicity of leukemia L1210 sublines in DBA-2 mice. Cancer Res (1971) 0.77
Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res (1981) 0.77
Immunomodulating effects of anticancer drugs: the example of adriamycin. Transplant Proc (1984) 0.77
Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol Res (1995) 0.77
Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods. J Natl Cancer Inst (1979) 0.77
Reversal of the in vitro methotrexate suppression of cell-mediated immune response by folinic acid and thymidine plus hypoxanthine. Cancer Res (1980) 0.77
In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function. Methods Find Exp Clin Pharmacol (1987) 0.77
Selectivity of inhibition by anticancer agents of mouse spleen immune effector functions involved in responses to sheep erythrocytes. Cancer Res (1978) 0.77
Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol Res (1994) 0.77
[An autopsy case of primary cutaneous plasmacytoma]. Rinsho Ketsueki (1989) 0.76
Third annual Pezcoller symposium: tumor suppressor genes. Cancer Res (1992) 0.76
Immunologic injury of renal homografts. J Exp Med (1971) 0.76
Selective imbalances of cellular immune responses by adriamycin. Recent Results Cancer Res (1980) 0.76
Transcardiac alteration of neutrophil function relates to myocardial ischaemia/reperfusion injury. Cardiovasc Res (1993) 0.76
Polymorphonuclear leukocytes-induced injury in hypoxic cardiac myocytes. Free Radic Biol Med (1994) 0.76
Alternatively spliced MHC class I mRNAs show specific deletion of sequences encoding the extracellular polymorphic domains. Int Immunol (1994) 0.76
Antitumor effects of kethoxal-bis(thiosemicarbazone) and 6-mercaptopurine in neonatally thymectomized mice. Proc Soc Exp Biol Med (1967) 0.76
In vitro studies on strain-dependent production of thymus-specific autoantibodies. J Exp Med (1973) 0.75
RNA recovery efficiency for cultured cells and organ-derived cell suspensions. Nucleic Acids Res (1994) 0.75
Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity. Natl Cancer Inst Monogr (1971) 0.75
The relationship of blood vessel proximity and time after radiolabeled thymidine administration to tumor cell population kinetics in a transplanted mouse mammary tumor. Am J Pathol (1981) 0.75